Abstract Body

Background

Hepatitis E virus (HEV), the causative agent of hepatitis E, is an important public health concern in many developing countries in Asia and Africa but is also endemic in industrialized countries including the USA. Globally, an estimated 20 million people are newly infected by HEV each year, resulting in >3.3 million cases of hepatitis E and 44,000 HEV-related deaths. Currently, there are no HEV-specific antivirals, and therapeutic options for HEV infection are limited to off-label use of ribavirin (RBV) and pegylated-interferon-α. There is an urgent need for highly effective drugs for the treatment of HEV infection, which can lead to fulminant hepatitis during pregnancy, neurological sequelae and hepatic failure in transplant patients. We report here on two prodrugs of a unique nucleotide polymerase inhibitor that exhibit promising antiviral profiles for the treatment of life-threatening HEV infection.

Methods

A small library of pre-selected molecules was screened for anti-HEV activity utilizing luciferase-based HEV subgenomic replicon and an HEV infection system. The selectivity of the lead compounds was established against other RNA viruses. Cytotoxicity, genotoxicity and off-target binding were also evaluated in vitro. 

Results

In vitro compound screening against HEV in an Huh7-derived HEV-3 Kernow-C1 p6/Gluc replicon assay identified two compounds, AT-2490 and AT-587, as potent inhibitors of HEV replication, with EC50 values of 29.4 and 66.9 nM, respectively.  The potent low nM potency was independently confirmed in HEV-1 Sar55 and HEV-3 p6 luciferase replicon assays in Huh-7-S10-3 cells. AT-2490 and AT-587 are >100-fold more potent against HEV than known nucleos(t)ide inhibitors such as sofosbuvir, bemnifosbuvir and RBV. AT-2490 and AT-587 are also active against flaviviruses (in the 0.02 to 0.3 µM range) but not coronaviruses. Mechanistically, the tri-phosphate (TP) metabolite of these two compounds has been shown to interact and inhibit HEV RdRp enzyme. Both compounds form high levels of the active TP in human hepatocytes. The active TP does not inhibit α, β, or γ DNA polymerases (IC50 >100 µM). Additional preclinical development studies, including animal efficacy studies, are ongoing. 

Conclusions

Prodrugs of a unique lead nucleotide polymerase inhibitor have been identified as highly potent pan-genotypic inhibitors of HEV which exhibit promising in vitro antiviral profiles for the treatment of life-threatening HEV infection.